These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 28532567

  • 1. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL, Chen KY, Kuo SW, Chang YL.
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract] [Full Text] [Related]

  • 2. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    Wang H, Zhang L, Liu W.
    J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
    [No Abstract] [Full Text] [Related]

  • 3. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y, Ishii Y, Oki M.
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract] [Full Text] [Related]

  • 4. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M.
    J Neurol; 2019 Dec; 266(12):3163-3166. PubMed ID: 31586260
    [No Abstract] [Full Text] [Related]

  • 5. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C, Sampaio L, Fernandes G.
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract] [Full Text] [Related]

  • 6. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR, Wu TW.
    Am J Ther; 2019 Nov; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract] [Full Text] [Related]

  • 7. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I, Chernoff M.
    Ann Oncol; 2017 Oct 01; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract] [Full Text] [Related]

  • 8. Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.
    De Groot M, Compter A, De Langen AJ, Brandsma D.
    J Neurol; 2020 Jan 01; 267(1):282-284. PubMed ID: 31701330
    [No Abstract] [Full Text] [Related]

  • 9. Prurigo nodularis and pembrolizumab: A therapeutic challenge.
    Fattore D, Panariello L, Annunziata MC, Fabbrocini G.
    Eur J Cancer; 2019 Mar 01; 110():8-10. PubMed ID: 30735833
    [No Abstract] [Full Text] [Related]

  • 10. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H, Takenoshita H, Inoue H, Kurihara Y, Sakaguchi C, Yano S, Hasuzawa N, Sakamoto S, Sakamoto R, Ashida K.
    J Oncol Pract; 2018 Jul 01; 14(7):449-451. PubMed ID: 29906213
    [No Abstract] [Full Text] [Related]

  • 11. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T.
    Intern Med; 2018 Nov 01; 57(21):3157-3162. PubMed ID: 29877257
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.
    Thakker M, Quadri K, Desai A, Illyas W, Kim MY, Desai S, Rager C.
    J Oncol Pract; 2019 Nov 01; 15(11):613-614. PubMed ID: 31580769
    [No Abstract] [Full Text] [Related]

  • 14. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    Boozalis E, Kwatra SG, Marrone KA.
    JAMA Oncol; 2019 Feb 01; 5(2):261-262. PubMed ID: 30286225
    [No Abstract] [Full Text] [Related]

  • 15. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD, Lai C, Hotton G, Anand G.
    Acute Med; 2019 Feb 01; 18(3):197-199. PubMed ID: 31536059
    [Abstract] [Full Text] [Related]

  • 16. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
    Gorospe L, García-Gómez-Muriel I, Pian-Arias HG, Gómez-Ramírez J, Rioja-Martín ME, Olmedo-García ME, Garrido-López P, Muñoz-Molina GM, Mezquita L.
    Ann Thorac Surg; 2020 Jun 01; 109(6):e397-e399. PubMed ID: 31846639
    [Abstract] [Full Text] [Related]

  • 17. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
    Tamura T, Akimoto E, Matsumoto C, Mori S, Nishi T, Kudo K, Kuyama S.
    J Thorac Oncol; 2018 Oct 01; 13(10):1606-1607. PubMed ID: 29730378
    [No Abstract] [Full Text] [Related]

  • 18. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M, Jantzem H, Quere G, Descourt R, Robinet G, Poureau PG.
    Eur J Cancer; 2019 Jul 01; 115():107-110. PubMed ID: 31132740
    [No Abstract] [Full Text] [Related]

  • 19. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
    Yoshida S, Miyamoto S, Naruse H, Ito J, Kinosita K, Kudo T, Hatanaka K, Yamamoto Y, Sakamoto N.
    Am J Gastroenterol; 2020 Jan 01; 115(1):13. PubMed ID: 31356230
    [No Abstract] [Full Text] [Related]

  • 20. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
    Cho HS, Lee KY, Hu CJ, Chung CC.
    Neurol India; 2018 Jan 01; 66(2):509-511. PubMed ID: 29547174
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.